Stock listing

Aligos Therapeutics, Inc.

Selected listing: A40LQ4 · LS · EUR · DE

Aligos Therapeutics, Inc. (Lang & Schwarz: A40LQ4), Health Technology. Latest release Oct 5, 2026: Aligos Therapeutics Announces Five Abstracts Accepted…

A40LQ4:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A40LQ4
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Aligos Therapeutics, Inc.

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

October 5, 2026

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

October 4, 2026

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

September 2, 2026

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

August 12, 2026

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

All Aligos Therapeutics, Inc. news →

Research Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. company profile

View the public company page for Aligos Therapeutics, Inc. on 6ix.

Aligos Therapeutics, Inc. news

Read company news and market updates connected to Aligos Therapeutics, Inc..

Aligos Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Aligos Therapeutics, Inc..